First human trial launches for new CMV vaccine candidate
NCT ID NCT06145178
Summary
This study was the first time a new vaccine candidate for cytomegalovirus (CMV) was tested in people. Researchers gave the vaccine, called SPYVLP01, to 120 healthy adults to check if it was safe and if it triggered an immune response. The main goal was to monitor for side effects and see how the body reacted to different doses, with and without immune-boosting additives.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CYTOMEGALOVIRUS INFECTIONS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Medicines Evaluation Unit
Manchester, United Kingdom
-
Velocity Bristol
Bristol, United Kingdom
Conditions
Explore the condition pages connected to this study.